

Nanda Nisha  
Form 3  
January 02, 2019

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB  
Number: 3235-0104  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â Nanda Nisha

(Last)

(First)

(Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

01/02/2019

3. Issuer Name **and** Ticker or Trading Symbol  
Loxo Oncology, Inc. [LOXO]

4. Relationship of Reporting  
Person(s) to Issuer

5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner

X Officer \_\_\_ Other

(give title below) (specify below)

Chief Development Officer

6. Individual or Joint/Group

Filing(Check Applicable Line)

X Form filed by One Reporting  
Person

\_\_\_ Form filed by More than One  
Reporting Person

C/O LOXO ONCOLOGY,  
INC.,Â 281 TRESSER  
BOULEVARD, 9TH FLOOR

(Street)

STAMFORD,Â CTÂ 06901

(City)

(State)

(Zip)

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

18,896

D

Â

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

4. Conversion  
or Exercise  
Price of  
Derivative

5. Ownership  
Form of  
Derivative  
Security:

6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

## Edgar Filing: Nanda Nisha - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (Right to Buy)	Â <u>(1)</u>	03/03/2024	Common Stock	16,983	\$ 1.184	D	Â
Employee Stock Option (Right to Buy)	Â <u>(1)</u>	03/03/2024	Common Stock	14,828	\$ 1.184	D	Â
Employee Stock Option (Right to Buy)	Â <u>(1)</u>	06/18/2024	Common Stock	4,557	\$ 3.648	D	Â
Employee Stock Option (Right to Buy)	Â <u>(1)</u>	12/18/2024	Common Stock	10,861	\$ 13.67	D	Â
Employee Stock Option (Right to Buy)	Â <u>(2)</u>	12/15/2025	Common Stock	9,228	\$ 31.69	D	Â
Employee Stock Option (Right to Buy)	Â <u>(3)</u>	09/14/2026	Common Stock	14,870	\$ 27	D	Â
Employee Stock Option (Right to Buy)	Â <u>(4)</u>	12/05/2026	Common Stock	18,375	\$ 26.27	D	Â
Employee Stock Option (Right to Buy)	Â <u>(5)</u>	03/14/2027	Common Stock	12,000	\$ 43.56	D	Â
Employee Stock Option (Right to Buy)	Â <u>(6)</u>	01/03/2028	Common Stock	75,000	\$ 84.88	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Nanda Nisha C/O LOXO ONCOLOGY, INC. 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901	Â	Â	Â Chief Development Officer	Â

## Signatures

/s/Jennifer Burstein, by power of attorney 01/02/2019

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option is fully vested and exercisable.

The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 16, 2016, then an additional 1/48th

(2) vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.

## Edgar Filing: Nanda Nisha - Form 3

- The stock option vests and becomes exercisable as to 1/48th of the total number of shares on October 15, 2016, then an additional 1/48th
- (3) vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.

- The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 6, 2017, then an additional 1/48th
- (4) vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.

- The stock option vests and becomes exercisable as to 1/48th of the total number of shares on April 15, 2017, then an additional 1/48th
- (5) vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.

- The stock option vests and becomes exercisable as to 1/24th of the total number of shares on March 4, 2018, then an additional 1/48th
- (6) vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.

Â

### Remarks:

ExhibitÂ ListÂ -Â ExhibitÂ 24.1Â -Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.